| Literature DB >> 29270192 |
Ran Tian1, Daiqing Yin1, Yanzhi Liu1, Inge Seim2, Shixia Xu1, Guang Yang1.
Abstract
Animals that are able to sustain life under hypoxic conditions have long captured the imagination of biologists and medical practitioners alike. Although the associated morphological modifications have been extensively described, the mechanisms underlying the evolution of hypoxia tolerance are not well understood. To provide such insights, we investigated genes in four major energy metabolism pathways, and provide evidence of distinct evolutionary paths to mammalian hypoxia-tolerance. Positive selection of genes in the oxidative phosphorylation pathway mainly occurred in terrestrial hypoxia-tolerant species; possible adaptations to chronically hypoxic environments. The strongest candidate for positive selection along cetacean lineages was the citrate cycle signaling pathway, suggestive of enhanced aerobic metabolism during and after a dive. Six genes with cetacean-specific amino acid changes are rate-limiting enzymes involved in the gluconeogenesis pathway, which would be expected to enhance the lactate removal after diving. Intriguingly, 38 parallel amino acid substitutions in 29 genes were observed between hypoxia-tolerant mammals. Of these, 76.3% were radical amino acid changes, suggesting that convergent molecular evolution drives the adaptation to hypoxic stress and similar phenotypic changes. This study provides further insights into life under low oxygen conditions and the evolutionary trajectories of hypoxia-tolerant species.Entities:
Keywords: adaptive evolution; convergent evolution; energy metabolism; hypoxia-tolerance; positive selection
Year: 2017 PMID: 29270192 PMCID: PMC5725996 DOI: 10.3389/fgene.2017.00205
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Positively selected genes (PSGs) in hypoxia-tolerant mammals after multiple-testing correction (FDR).
| Order | Species | Habitat | Total PSGs numbers | PSGs | Numbers/Proportions (%) of PSGs in pathway |
|---|---|---|---|---|---|
| Cetacea | cetacean | Marine | 8 | EMP/GNG 2 (4.1) | |
| TCA 2 (6.9) | |||||
| PM 1 (2.9) | |||||
| OXPHOS 4 (3.6) | |||||
| Pinnipedia | Weddell seal | Marine | 1 | TCA 1 (3.4) | |
| PM 1 (2.9) | |||||
| Sirenia | West Indian manatee | Marine | 1 | TCA 1 (3.4) | |
| Artiodactyla | Tibetan yak | Highland | 4 | EMP/GNG 2 (4.1) | |
| PM 1 (2.9) | |||||
| OXPHOS 2 (1.8) | |||||
| Artiodactyla | Tibetan antelope | Highland | 1 | OXPHOS 1 (0.9) | |
| Rodentia | naked mole rat | Subterranean | 2 | OXPHOS 2 (1.8) |
Thirty-eight parallel amino acid substitutions in 29 genes in hypoxia-tolerant species.
| Branches | Gene name | Pathway | Site | ΔSSLS | AA change | Radical/Conservative changes | Functional sites (identity with sites of human) |
|---|---|---|---|---|---|---|---|
| a vs. p | OXPHOS | 397 | L-V | C | |||
| a vs. g | EMP/GNG | 395 | I-T | R | |||
| a vs. v | TCA | 54 | I-V | C | Modified residue: 50, N6-acetyllysine; alternate | ||
| OXPHOS | 19 | A-T | R | ||||
| OXPHOS | 11 | A-L | R | ||||
| 25 | A-S | R | |||||
| TCA | 344 | M-T | R | ||||
| OXPHOS | 269 | R-Q | R | ||||
| EMP/GNG | 65 | R-H | C | ||||
| EMP/GNG | 412 | D-E | C | ||||
| a vs. x | PM | 363 | A-T | R | |||
| OXPHOS | 31 | P-S | R | Transit peptide 1-68 | |||
| OXPHOS | 16 | D-N | R | ||||
| EMP/GNG | 65 | R-H | C | Binding site: 62, Interaction with carboxyl group of phosphoglycerates | |||
| p vs. q | PM | 287 | G-D | R | |||
| EMP/GNG | 557 | T-M | R | Domain: Hexokinase 2: 477–912; region: 489–923: Catalytic; region: 531–661: Hexokinase small subdomain 2 | |||
| q vs. v | OXPHOS | 335 | Y | P-T | C | ||
| 339 | Y | Y-P | R | ||||
| g vs. q | OXPHOS | 54 | I-V | C | |||
| g vs. v | TCA, PM | 265 | A-T | R | |||
| EMP/GNG | 846 | E-Q | R | Domain: Hexokinase 2: 464–905; region: Hexokinase large subdomain 2: 655–894 | |||
| PM | 274 | V-L | C | ||||
| OXPHOS | 423 | P-Q | R | ||||
| g vs. x | PM | 5 | R-C | R | |||
| PM | 333 | S-F | R | Modified residue: 358, N6-acetyllysine; alternate | |||
| x vs. q | TCA, OXPHOS | 38 | Y | R-Q | R | ||
| x vs. v | TCA | 602 | Q-R | R | |||
| OXPHOS | 667 | R-Q | R | ||||
| 691 | A-S | R | |||||
| OXPHOS | 18 | I-V | C | ||||
| OXPHOS | 98 | R-H | C | ||||
| OXPHOS | 24 | Q-R | R | ||||
| OXPHOS | 102 | L-F | R | ||||
| PM | 47 | T-M | R | Domain: FAD-binding PCMH-type: 62–265 | |||
| OXPHOS | 34 | R-C | R | Transit peptide: Mitochondrion: 1–35; chain: 36–377 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial | |||
| 355 | R-H | C | |||||
| OXPHOS | 340 | G-E | R | Chain: 36–355: NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial) | |||
| OXPHOS | 34 | F-C | R | ||||
| EMP/GNG | 654 | M-L | C | ||||
| EMP/GNG | 65 | R-H | C |